This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yen, Y. Articles by Cheng, Y.-C. Search for Related Content PubMed PubMed Citation Articles by Yen, Y. Articles by Cheng, Y.-C.

Characterization of a Hydroxyurea-resistant Human KB Cell Line with Supersensitivity to 6-Thioguanine¹

Department of Pharmacology, Yale University, New Haven, Connecticut 06510

Hydroxyurea (HU) is currently used in the clinic for the treatment of chronic myelogenous leukemia, head and neck carcinoma, and sarcoma. One of its drawbacks, however, is the development of HU resistance. To study this problem, we developed a HU-resistant human KB cell line which exhibits a 15-fold resistance to HU. The characterization of this HU-resistant phenotype revealed a gene amplification of the M2 subunit of ribonucleotide reductase (RR), increased levels of M2 mRNA and protein, and a 3-fold increase of RR activity. This HU-resistant cell line also expressed a "collateral sensitivity" to 6-thioguanine (6-TG), with a 10-fold decrease in the dose inhibiting cell growth by 50% as compared to the KB parental line. The mechanism responsible for this supersensitivity to 6-TG is believed to be related to an increasingly efficient conversion of 6-TG to its triphosphate form, which is subsequently incorporated into DNA. After passage of the resistant cells in the absence of HU, the cell line reverts. The revertant cells lose their resistance to HU and concomitantly their sensitivity to 6-TG. This phenomenon is due to the return of RR to levels comparable to that of the KB parental cell line. These observations and their relevance to cancer chemotherapy will be discussed in this paper. Our results suggest that a clinical protocol could be designed which would allow for a lower dose of 6-TG to be used by taking advantage of the increased RR activity in HU-refractory cancer patients. Two drugs which display collateral sensitivity are known as a "Ying-Yang" pair. Alternate treatment with two different Ying-Yang pairs is the rationale for the "Ying-Yang Ping-Pong" theory in cancer treatment. This rationale allows for effective cancer chemotherapy with reduced toxicity.

¹ Supported by NIH Grant CA 44358.

² To whom requests for reprints should be addressed, at Yale University School of Medicine, Department of Pharmacology, SHM-B313, 333 Cedar Street, New Haven, CT 06510-8066.

Received 3/29/94. Accepted 6/ 2/94.

This article has been cited by other articles:

				L. P. Jordheim, O. Guittet, M. Lepoivre, C. M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol. Cancer Ther., August 1, 2005; 4(8): 1268 - 1276. [Abstract] [Full Text] [PDF]

				S. Wadler, D. Makower, C. Clairmont, P. Lambert, K. Fehn, and M. Sznol Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion J. Clin. Oncol., May 1, 2004; 22(9): 1553 - 1563. [Abstract] [Full Text] [PDF]

				W. Gao, W. Lam, S. Zhong, C. Kaczmarek, D. C. Baker, and Y.-C. Cheng Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds Cancer Res., January 15, 2004; 64(2): 678 - 688. [Abstract] [Full Text] [PDF]

				J. Shao, B. Zhou, L. Zhu, W. Qiu, Y.-C. Yuan, B. Xi, and Y. Yen In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase Cancer Res., January 1, 2004; 64(1): 1 - 6. [Abstract] [Full Text] [PDF]

				B. Zhou, X. Liu, X. Mo, L. Xue, D. Darwish, W. Qiu, J. Shih, E. B. Hwu, F. Luh, and Y. Yen The Human Ribonucleotide Reductase Subunit hRRM2 Complements p53R2 in Response to UV-Induced DNA Repair in Cells with Mutant p53 Cancer Res., October 15, 2003; 63(20): 6583 - 6594. [Abstract] [Full Text] [PDF]

				Y. Yen Ribonucleotide Reductase Subunit One as Gene Therapy Target: Commentary re: M-Y. Cao et al., Adenovirus-mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003. Clin. Cancer Res., October 1, 2003; 9(12): 4304 - 4308. [Full Text] [PDF]

				J. Murren, M. Modiano, C. Clairmont, P. Lambert, N. Savaraj, T. Doyle, and M. Sznol Phase I and Pharmacokinetic Study of Triapine, a Potent Ribonucleotide Reductase Inhibitor, Administered Daily for Five Days in Patients with Advanced Solid Tumors Clin. Cancer Res., September 15, 2003; 9(11): 4092 - 4100. [Abstract] [Full Text] [PDF]

				A. NAGANUMA, N. MIURA, S. KANEKO, T. MISHINA, S. HOSOYA, S. MIYAIRI, T. FURUCHI, and S. KUGE GFAT as a target molecule of methylmercury toxicity in Saccharomyces cerevisiae FASEB J, May 1, 2000; 14(7): 968 - 972. [Abstract] [Full Text]

				Y.-G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line Cancer Res., September 1, 1999; 59(17): 4204 - 4207. [Abstract] [Full Text] [PDF]

				S. J. Wong, M. S. Myette, J. P. Wereley, and C. R. Chitambar Increased Sensitivity of Hydroxyurea-resistant Leukemic Cells to Gemcitabine Clin. Cancer Res., February 1, 1999; 5(2): 439 - 443. [Abstract] [Full Text] [PDF]